The offering provides a modest cash infusion for working capital but creates ~1.5% dilution. Monitor the company's next quarterly filing for any change in operating trends or cash burn rate. The 91-day lock-up limits near-term secondary supply, but the participation right gives the investor a potential overhang on future financings.
Price Chart
Executive Summary
China Pharma Holdings priced a registered direct offering of 2.5 million shares at $2.00 per share for gross proceeds of $5 million, with FT Global Capital as placement agent. The company will use net proceeds for working capital and general corporate purposes. The offering represents approximately 1.5% dilution relative to the current market cap and includes a 91-day lock-up on further equity issuances and a 3-month participation right for the investor in future financings.
Key Facts
- Priced 2,500,000 shares at $2.00 per share for $5,000,000 gross proceeds
- Closing expected on or around July 23, 2026
- FT Global Capital, Inc. acting as exclusive placement agent with a 7.0% cash fee
- Proceeds to be used for working capital and general corporate purposes
- 91-day lock-up on subsequent equity sales and 3-month participation right for investor up to 40% of future financings
- Offered under effective shelf registration statement on Form S-3 (File No. 333-276481)
Financial Impact
Gross proceeds of $5,000,000 from sale of 2.5M shares at $2.00/share; net proceeds after placement agent fee (7%) and estimated expenses approximately $4.5M
Risk Factors
- Dilution of existing shareholders by approximately 1.5% from the new shares
- Potential overhang from the investor's 40% participation right in future financings within 3 months
- No financial performance data provided; company's ability to generate returns on the raised capital is uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-080475 |
| Document: ea029892101ex10-2.htm | 0001213900-26-080475 |
| Document: ea0298921-8k_china.htm | 0001213900-26-080475 |
| Document: ea029892101ex5-1.htm | 0001213900-26-080475 |
| Document: ea029892101ex99-1.htm | 0001213900-26-080475 |
| Document: 0001213900-26-080475-index-headers.html | 0001213900-26-080475 |
| Document: 0001213900-26-080475-index.html | 0001213900-26-080475 |
| Document: 0001213900-26-080475.txt | 0001213900-26-080475 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 23, 2026 13w ago | 424B5 | $1.85 $0.7279 | ▲ +60.65% | ▲ +65.21% | $0.6438 (+65.20%) |
Jul 22, 2026 13w ago | 8-K | $1.85 $0.7279 | ▼ −60.65% | ▼ −65.21% | $0.6438 (−65.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers